FATE Therapeutics Inc.
FATE Therapeutics Inc. is listed today as Fate Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2020 | $50 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Apr 2020 | $50 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Nov 2016 | $57 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Aug 2016 | $10 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| May 2015 | $8 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| May 2012 | $9 M | No. 2 | $2 to $10 million | equity | SEC | |
| Nov 2009 | $36 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
FATE Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2020).
SEC Form D · Jul 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jul 2020
That is all the official record says: FATE Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of FATE Therapeutics Inc. are on record.
Investors#
18 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Arch Venture Fund VI LP | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Arch Venture Partners VI LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Arch Venture Partners VI LP | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Ovp Venture Partners VII LP | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Ovp VII Entrepreneurs Fund LP | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Polaris Venture Management Co. V, L.L.C. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Polaris Venture Partners Entrepreneurs' Fund V, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Polaris Venture Partners Founders' Fund V, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Polaris Venture Partners Special Founders' Fund V, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Polaris Venture Partners V, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| RedCo II Master Fund, L.P. | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner, director (Form 3, 2025) | SEC Form 3 |
| Redmile Group, LLC | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner, director (Form 3, 2018) | SEC Form 3 |
| VEF Management V, LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Venrock Associates V LP | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Venrock Entrepreneurs Fund V, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Venrock Management V, LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Venrock Partners Management V, LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Venrock Partners V L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 18 investors.
Largest shareholders today
Institutions holding Fate Therapeutics, Inc. shares, as of Sep 30, 2026.
- Redmile Group, LLC$31 M10.59%
- BlackRock, Inc.$17 M5.84%
- Vanguard Portfolio Management LLC$12 M4.08%
- Acadian Asset Management LLC$11 M3.92%
- Vanguard Capital Management LLC$11 M3.70%
- Two Sigma Investments, LP$9 M3.21%
- Johnson & Johnson$8 M2.78%
- Renaissance Technologies LLC$6 M1.95%
- Arrowstreet Capital, Limited Partnership$6 M1.95%
- Millennium Management LLC$5 M1.78%
- Goldman Sachs Group Inc$5 M1.70%
- Qube Research & Technologies Ltd$4 M1.37%
- Susquehanna International Group, LLP$4 M1.29%
- Geode Capital Management, LLC$3 M1.09%
- Assenagon Asset Management S.A.$3 M1.08%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Cindy Tahl | Executive officer | Jul 2020 |
| J. Scott Wolchko | Executive officer | Jul 2020 |
| Chris D. Storgard | Executive officer | Dec 2016 |
| Cindy D. Tahl | Executive officer | Dec 2016 |
| Daniel D. Shoemaker | Executive officer | Dec 2016 |
| Stewart S. Abbot | Executive officer | Dec 2016 |
| Christian Weyer | Executive officer | May 2015 |
| Daniel Shoemaker | Executive officer | May 2015 |
| Scott Wolchko | Executive officer | Aug 2012 |
| William T. Rastetter | Executive officer | Aug 2012 |
| Daniel T. Shoemaker | Executive officer | Apr 2011 |
| John Mendlein | Executive officer | Apr 2011 |
| PAUL Grayson | Executive officer | Dec 2009 |
| J. Scott Wolchko | Director | Jul 2020 |
| John Mendlein | Director | Jul 2020 |
| Karin Jooss | Director | Jul 2020 |
| Michael Lee | Director | Jul 2020 |
| Robert Epstein | Director | Jul 2020 |
| Robert Hershberg | Director | Jul 2020 |
| Shefali Agarwal | Director | Jul 2020 |
| Timothy Coughlin | Director | Jul 2020 |
| William Rastetter | Director | Jul 2020 |
| Amir Nashat | Director | Apr 2020 |
| Amir S. Nashat | Director | Dec 2016 |
| John S. Mendlein | Director | Dec 2016 |
| Mark J. Enyedy | Director | Dec 2016 |
| Robert S. Epstein | Director | Dec 2016 |
| Timothy P. Coughlin | Director | Dec 2016 |
| William S. Rastetter | Director | Dec 2016 |
| Christian Weyer | Director | May 2015 |
| Mark Enyedy | Director | May 2015 |
| Bryan E. Roberts | Director | Aug 2012 |
| Carl Weissman | Director | Aug 2012 |
| Mark T. Enyedy | Director | Aug 2012 |
| Robert T. Nelsen | Director | Aug 2012 |
| William T. Rastetter | Director | Aug 2012 |
| PAUL Grayson | Director | Dec 2009 |
About
A clinical-stage biopharmaceutical company in San Diego, United States.
Went public since 2013. Its SEC number is that of a company listed on a stock exchange.